In fact, here we demonstrated in vitro and in a xenograft model that LKB1 loss increases uveal melanoma cells' sensitivity to the combination of the SLC8A1 inhibitor, KB‐R7943 with MitoQ, the only mitochondrial antioxidant that has safely been used in clinical trials (Smith & Murphy, 2010; Rossman et al, 2018). Here, STK11 is linked to uveal melanoma.